JPRN-UMIN000012508招募中未知
Teneligliptin effects on DPP-4 and glucagon concentrations in the serum during a meal test in patients with type 2 diabetes - TENDERNESS
Department of Endocrinology and Metabolism,Dokkyo Medical University0 个研究点目标入组 20 人开始时间: 2013年12月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who have type 1 diabetes and/or secondary diabetes (Cushing syndrome or acromegaly). 2.Contraindication for DPP-4 inhibitors 3.Patients who have heart failure (NYHA category 3-4) 4.Patients who are prone to QT prolongation. 5 Alcohol intake excess. 6.Patients who are pregnant or may be pregnant 7.History of myocardial infarction 8.Patients who have received GLP-1 receptor agonists
研究者
相似试验
已完成
4 期
Sitagliptin and Glucagon CounterregulationType 2 DiabetesNCT02256189Lund University28
已完成
4 期
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 DiabetesDiabetesHypoglycemiaNCT01147276Lund University28
尚未招募
不适用
Effect of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin on Forearm Endothelial Function in Diabeticsdiabetic patientJPRN-jRCT1091220223Bonpei Takase30
已完成
不适用
Vildagliptin on Gastric AccommodationHealthyNCT03500900Universitaire Ziekenhuizen KU Leuven20
终止
2 期
Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)Glucose HomeostasisNCT00947011Johns Hopkins University12